FDMT (4D Molecular Therapeutics Inc) Total Business Assets
This chart of financial quotes for 4D Molecular Therapeutics (FDMT) assets, which reach 483.10, highlights a business model where viral vector creation and testing are outsourced to third-party contractors. 4D Molecular Therapeutics (FDMT) minimizes risks by developing gene therapies for the heart, lungs, and eyes. A competitive advantage is driven by a unique AAV virus modification system and intellectual property protection within the ophthalmology segment.
Analytical breakdowns for 4D Molecular Therapeutics
A comparative asset analysis allows investors to assess the actual scale of a company's resources relative to its market capitalization. This metric is calculated inversely via return on assets (ROA), reflecting the total volume of assets and liabilities. For 4D Molecular Therapeutics (FDMT), this indicator confirms a high concentration of capital within its gene therapy R&D platform alongside the diversification of clinical pipelines. The trend in total asset value on GURU.Markets helps identify hidden balance sheet imbalances.